invoX subsidiary F-star Therapeutics has  with Takeda to develop multi-specific antibodies.

The partnership will use F-star’s fully-human Fcab and tetravalent mAb² platforms to analyse and develop immunotherapies for cancer.

The companies will work on the development of as-yet-undisclosed new Fcab domains against immuno-oncology targets. 

Takeda will obtain an exclusive global royalty-bearing licence to carry out research, development and marketing of the antibodies containing Fcab domains that will result from the partnership.

The rights for researching, developing and marketing antibodies with other Fcab domains will be retained by F-star. 

F-star is eligible to receive an undisclosed upfront payment and investment for research during the partnership period.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Takeda will make contingent payments of $1bn to F-star on meeting development and marketing milestones. 

F-star will also receive royalty payments on net yearly sales of any product arising from the licence.

F-star Therapeutics head and chief scientific officer Neil Brewis stated: “We are delighted to expand our relationship with Takeda which shares our vision of developing pioneering multi-specific immunotherapies so more people with cancer can live longer with improved lives. 

“This strategic collaboration leverages the capabilities of both companies by combining F-star’s clinically validated Fcab and mAb² platforms with Takeda’s unique understanding of the immune system and its ability to progress drugs to the clinic.”

In May 2023, Takeda and KSQ Therapeutics extended their immuno-oncology collaboration for novel tumour-intrinsic targets.

ɫ Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The ɫ Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now